Methylene blue as an antimalarial agent

Redox Report

Volumn 8, Issue 5, 2003, Pages 272-275

  Schirmer, R Heiner ^a   Coulibaly, Boubacar ^a,b   Stich, August ^c   Scheiwein, Michael ^a,b   Merkle, Heiko ^a,b   Eubel, Jana ^a   Becker, Katja ^d   Becher, Heiko ^a   Müller, Olaf ^a   Zich, Thomas ^e   Schiek, Wolfgang ^e   Kouyaté, Bocar ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Ctr de Rech/Sante de Nouna (CRSN)   (Burkina Faso)

^c Medical Mission Institute   (Germany)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

^e DSM Fine Chemicals Austria Nfg GmbH & Co KG   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; FANSIDAR; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTATHIONE REDUCTASE; METHYLENE BLUE;

ANTIMALARIAL ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG EXCRETION; DRUG INDICATION; DRUG METABOLISM; HUMAN; MALARIA FALCIPARUM; METHEMOGLOBINEMIA; PILOT STUDY; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIMALARIALS; CLINICAL TRIALS; GLUTATHIONE REDUCTASE; HUMANS; MALARIA, FALCIPARUM; METHYLENE BLUE; OXIDATION-REDUCTION; PLASMODIUM FALCIPARUM;

PLASMODIUM FALCIPARUM;

EID: 9144221396     PISSN: 13510002     EISSN: None     Source Type: Journal    
DOI: 10.1179/135100003225002899     Document Type: Article

References (36)

1. Guttmann P, Ehrlich P. Über die Wirkung des Methylenblau bei Malaria. Berl Klin Wochenschr 1891; 28: 953-956.
2. Mansouri A, Lurie AA. Concise review: methemoglobinemia. Am J Hematol 1993; 42: 7-12.
3. Coleman MD, Coleman NA. Drug-induced methaemoglobinaemia. Treatment issues. Drug Saf 1996; 14: 394-405.
4. Peter C, Hongwan D, Kupfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 2000; 56: 247-250.
5. Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prove A, Vermorken JB. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000; 82: 291-294.
6. Anstey NM, Hassanali MY, Mlalasi J, Manyenga D, Mwaikambo ED. Elevated levels of methaemoglobin in Tanzanian children with severe and uncomplicated malaria. Trans R Soc Trop Med Hyg 1996; 90: 147-151.
7. Quandt KS, Hultquist DE. Flavin reductase: sequence of cDNA from bovine liver and tissue distribution. Proc Natl Acad Sci USA 1994; 91: 9322-9326.
8. Färber PM, Becker K, Müller S, Schirmer RH, Franklin RM. Molecular cloning and characterization of a putative glutathione reductase gene, the PfGR2 gene, from Plasmodium falciparum. Eur J Biochem 1996; 239: 655-661.
9. Atamna H, Pascarmona G, Ginsburg H. Hexose-monophosphate shunt activity in intact Plasmodium falciparum-infected erythrocytes and in free parasites. Mol Biochem Parasitol 1994; 67: 79-89.
10. Vennerstrom JL, Makler MT, Angerhofer CK, Williams JA. Antimalarial dyes revisited: xanthenes, azines, oxazines, and thiazines. Antimicrob Agents Chemother 1995; 39: 2671-2677.
11. Atamna H, Krugliak M, Shalmiev G, Deharo E, Pescarmona G, Ginsburg H. Mode of antimalarial effect of methylene blue and some of its analogues on Plasmodium falciparum in culture and their inhibition of P. vinckei petteri and P. yoelii nigeriensis in vivo. Biochem Pharmacol 1996; 51: 693-700.
12. Thurston JP. The chemotherapy of Plasmodium berghei. Resistance to drugs. Parasitology 1953; 43: 246-252.
13. Ridley RG. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 2002; 415: 686-693.
14. Akompong T, Ghori N, Haldar K. In vitro activity of riboflavin against the human malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother 2000; 44: 88-96.
15. Färber PM, Arscott LD, Williams CH Jr, Becker K, Schirmer RH. Recombinant Plasmodium falciparum glutathione reductase is inhibited by the antimalarial dye methylene blue. FEBS Lett 1998; 422: 311-314.
16. Gilberger TW, Schirmer RH, Walter RD, Müller S. Deletion of the parasite-specific insertions and mutation of the catalytic triad in glutathione reductase from chloroquine-sensitive Plasmodium falciparum 3D7. Mol Biochem Parasitol 2000; 107: 169-179.
17. Sarma GN, Savvides SN, Becker K, Schirmer M, Schirmer RH, Karplus PA. Glutathione reductase of the malarial parasite Plasmodium falciparum: crystal structure and inhibitor development. J Mol Biol 2003; 328: 893-907.
18. Becker K, Rahlfs S, Nickel C, Schirmer RH. Glutathione - function and metabolism in the malarial parasite Plasmodium falciparum. Biol Chem 2003; 384: 551-566.
19. Luond RM, McKie JH, Douglas KT, Dascombe MJ, Vale J. Inhibitors of glutathione reductase as potential antimalarial drugs. Kinetic cooperativity and effect of dimethyl sulphoxide on inhibition kinetics. J Enzyme Inhib 1998; 13: 327-345.
20. Davioud-Charvet E, Delarue S, Biot C et al. A prodrug form of a Plasmodium falciparum glutathione reductase inhibitor conjugated with a 4-anilinoquinoline. J Med Chem 2001; 44: 4268-4276.
21. Ginsburg H. A double-headed prodrug that overcomes chloroquine resistance. Trends Parasitol 2002; 18: 103.
22. Zhang YA, Hempelmann E, Schirmer RH. Glutathione reductase inhibitors as potential antimalarial drugs. Effects of nitrosoureas on Plasmodium falciparum in vitro. Biochem Pharmacol 1988; 37: 855-860.
23. Dubois VL, Platel DF, Pauly G, Tribouley-Duret J. Plasmodium berghei: implication of intracellular glutathione and its related enzyme in chloroquine resistance in vivo. Exp Parasitol 1995; 81: 117-124.
24. Müller S, Gilberger TW, Krnajski Z, Lüersen K, Meierjohann S, Walter RD. Thioredoxin and glutathione system of malaria parasite Plasmodium falciparum. Protoplasma 2001; 217: 43-49.
25. Peters W. Chemotherapy and Drug Resistance in Malaria. London: Academic Press, 1970.
26. Scheiwein M. Pathophysiologische und chemotherapeutische Mechanismen der Glutathionreduktase-Inaktivierung bei Malaria. MD thesis, Heidelberg, Germany: Heidelberg University 2001.
27. Beutler E, Mitchell M. Special modifications of the fluorescent screening method for glucose-6-phosphate dehydrogenase deficiency. Blood 1968; 32: 816-818.
28. Becker K, Krebs B, Schirmer RH. Protein-chemical standardization of the erythrocyte glutathione reductase activation test (EGRAC test). Application to hypothyroidism. Int J Nutr Res 1991; 61: 180-187.
29. Brewer GJ, Tarlov AR, Alving AS. The methemoglobin reduction test for primaquine-type sensitivity of erythrocytes. A simplified procedure for detecting a specific hypersusceptibility for drug hemolysis. JAMA 1962; 180: 386-388.
30. Ademowo OG, Falusi AG. Molecular epidemiology and activity of erythrocyte G6PD variants in a homogeneous Nigerian population. East Afr Med J 2002; 79: 42-44.
31. Ruwende C, Hill A. Glucose-6-phosphate dehydrogenase deficiency and malaria. J Mol Med 1998; 76: 581-588.
32. Beutler E. G6PD deficiency. Blood 1994; 84: 3613-3636.
33. Rieckmann K, Cheng Q. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum must be delayed in Africa. Trends Parasitol 2002; 18: 293-294.
34. Antonov L, Gergov G, Petrov V, Kubista M, Nygren J. UV-Vis spectroscopic and chemometric studies on the aggregation of ionic dyes in water. Talanta 1999; 49: 99-106.
35. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000; 44: 235-249.
36. Schirmer RH, Müller JG, Krauth-Siegel RL. Disulfide-reductase inhibitors as chemotherapeutic agents: the design of drugs for trypanosomiasis and malaria. Angew Chem Int Edn 1995; 34: 141-154.